Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Shares Outstanding (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Shares Outstanding for 3 consecutive years, with $381.4 million as the latest value for Q3 2022.

  • On a quarterly basis, Shares Outstanding changed N/A to $381.4 million in Q3 2022 year-over-year; TTM through Sep 2022 was $381.4 million, a N/A change, with the full-year FY2020 number at $124.0, changed N/A from a year prior.
  • Shares Outstanding was $388.5 million for Q4 2022 at GeneDx Holdings, up from $381.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $388.5 million in Q4 2022 to a low of $124.0 in Q3 2020.
  • A 3-year average of $189.3 million and a median of $241.4 million in 2021 define the central range for Shares Outstanding.
  • Biggest YoY gain for Shares Outstanding was 197705121.77% in 2022; the steepest drop was 3332.16% in 2022.
  • GeneDx Holdings' Shares Outstanding stood at $124.0 in 2020, then soared by 8926311.29% to $11.1 million in 2021, then skyrocketed by 3346.0% to $381.4 million in 2022.
  • Per Business Quant, the three most recent readings for WGS's Shares Outstanding are $381.4 million (Q3 2022), $379.9 million (Q2 2022), and $245.2 million (Q1 2022).